Role of Statin on the Gastric Inflammation in Patients at High Risk of Gastric Cancer

Not Applicable

Completed

• Conditions: Early Gastric Cancer or Gastric Adenoma

• Registration Number: NCT01813994
• Lead Sponsor: Yonsei University

Brief Summary

Statins are commonly used as cholesterol-lowering medications and have shown effectiveness in the primary and secondary prevention of heart attack and stroke. In addition, several recent studies of human cancer cell lines and animal tumor models indicate that statins may have chemopreventive properties through the arresting of cell-cycle progression. The chemopreventive effect of statins was demonstrated in some kind of human tumors including colorectal cancer. In addition, recent one large epidemiologic study showed that statins decreased risk of gastric cancer. On the other hands, it has been well known that Helicobacter pylori infection induces gastric atrophy and intestinal metaplasia, which are premalignant lesions of gastric cancer. Progression of these premalignant lesions could be limited by H. pylori eradication. In addition, a recent double blind randomization study revealed that simvastatin as adjuvant to standard therapy improves significantly the H. pylori eradication rate. Therefore, investigators conjecture that statins may have an adjuvant role for inhibition of gastric carcinogenesis. investigators aim to evaluate the role of statins in gastric carcinogenesis by observing the changes of gastric inflammation under statins.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2013-03-07
• Study First Submitted QC: 2013-03-14
• Study First Posted: 2013-03-19
• Study Start: 2014-11
• Primary Completion: 2018-06-19
• Study Completion: 2018-06-19
• Status Verified: 2018-12
• Last Update Submitted: 2019-03-27
• Last Update Posted: 2019-03-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

1. Age, between 20 and 70
2. Early gastric cancer or adenoma which is achieved curative resection by endoscopic submucosal dissection
3. ECOG performance status 0 or 1

Read More

Exclusion Criteria

1. Previous subtotal gastrectomy or gastrostomy
2. Repeated endoscopic submucosal dissection
3. Two or more synchronous lesions
4. Presence of gastric or duodenal ulcer except artificial ulcer due to endoscopic submucosal dissection
5. History of drugs which are able to induce gastric ulcer including aspirin, NSAIDs, and steroid (30 days or more, within 1 year at the time of screening
6. Indication of statins, including dyslipidemia, myocardial infarction, and heart failure.
7. Develop of complications caused by endoscopic submucosal dissection, including bleeding, perforation, and pneumonia
8. LDL < 70 mg/dL
9. Allergy to statins
10. Pregnancy or breast milk feeding
11. Active infection
12. Significant cardiopulmonary disease
13. Active hepatitis or severe hepatic dysfunction
14. Severe renal dysfunction
15. Severe bone marrow dysfunction

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Proportion of the patients with high-risk (III/IV) OLGA stages	6 months from the start of taking the statins	patients with high-risk OLGA stages will be assessed by histologic examinations

Trial Locations

Locations (1)

Severance Hospital; 🇰🇷 Seoul, Korea, Republic of